First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
Recruiting now · Phase 1/Phase 2
Conditions studied: Hepatocellular Carcinoma
In brief
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.
Key facts
- Study ID
- NCT06795022
- Run by
- AstraZeneca
- People needed
- 304
- Starts
- 2025-03-27
- Expected to finish
- 2028-07-25
- Last updated by the study team
- 2026-04-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — St Louis, Missouri, United States (enrolling)
- Research Site — Shatin, Hong Kong (enrolling)
- Research Site — Kashiwa, Japan (enrolling)
- Research Site — Yokohama, Japan (enrolling)
- Research Site — Guangzhou, China (enrolling)
- Research Site — Seoul, South Korea (enrolling)
- Research Site — Houston, Texas, United States (enrolling)
- Research Site — Shanghai, China (enrolling)
- Research Site — Taipei, Taiwan (enrolling)
- Research Site — Taoyuan, Taiwan (enrolling)
- Research Site — Pokfulam, Hong Kong
- Research Site — Los Angeles, California, United States
- Research Site — Baltimore, Maryland, United States
- Research Site — Hackensack, New Jersey, United States
- Research Site — Chengdu, China
- Research Site — Harbin, China
- Research Site — La Jolla, California, United States
- Research Site — Seoul, South Korea
- Research Site — Barcelona, Spain
- Research Site — Pamplona, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.